E-LIB Suche - Ergebnisse für: Bruno, Giacomo Matteo

1

Economic Evaluation for Palbociclib Plus Fulvestrant vs Rib..:

Colombo, Giorgio Lorenzo ; Valentino, Maria Chiara ; Fabi, Alessandra...
Therapeutics and Clinical Risk Management. 19 (2023) - p. 301-312 , 2023

Link: https://doi.org/10.2147/..

2

Economic Burden of Non-Alcoholic Steatohepatitis (NASH) Amo..:

Torre, Enrico ; Di Matteo Snr, Sergio ; Bruno, Giacomo Matteo...
ClinicoEconomics and Outcomes Research. 14 (2022) - p. 607-618 , 2022

Link: https://doi.org/10.2147/..

3

Overview of Nutraceuticals and Cardiometabolic Diseases fol..:

Bruno, Giacomo Matteo ; Dovera, Federico ; Ciccarone, Antonio.
Endocrines. 3 (2022) 2 - p. 255-295 , 2022

Link: https://doi.org/10.3390/..

4

Economic Impact of COVID-19 Lockdown on Italian NHS: Focus ..:

Torre, Enrico ; Colombo, Giorgio Lorenzo ; Di Matteo, Sergio...
ClinicoEconomics and Outcomes Research. 13 (2021) - p. 503-518 , 2021

Link: https://doi.org/10.2147/..

5

Omalizumab for Severe Allergic Asthma Treatment in Italy: A..:

Canonica, Giorgio Walter ; Colombo, Giorgio Lorenzo ; Rogliani, Paola...
Risk Management and Healthcare Policy. 13 (2020) - p. 43-53 , 2020

Link: https://doi.org/10.2147/..

6

Cost-Utility Analysis of Saxagliptin/Dapagliflozin Versus G..:

Torre, Enrico ; Bruno, Giacomo Matteo ; Di Matteo, Sergio...
Health Services Insights. 13 (2020) - p. 117863292092998 , 2020

Link: https://doi.org/10.1177/..

7

Shadow cost of oral corticosteroids-related adverse events:..:

Canonica, Giorgio Walter ; Colombo, Giorgio Lorenzo ; Bruno, Giacomo Matteo...
World Allergy Organization Journal. 12 (2019) 1 - p. 100007 , 2019

Link: https://doi.org/10.1016/..

8

Omalizumab and long-term quality of life outcomes in patien..:

Colombo, Giorgio Lorenzo ; Di Matteo, Sergio ; Martinotti, Chiara...
Therapeutic Advances in Respiratory Disease. 13 (2019) - p. 175346661984135 , 2019

Link: https://doi.org/10.1177/..

9

Budget impact model of secukinumab for the treatment of mod..:

Colombo, Giorgio Lorenzo ; Di Matteo, Sergio ; Martinotti, Chiara...
ClinicoEconomics and Outcomes Research. 10 (2018) - p. 477-491 , 2018

Link: https://doi.org/10.2147/..

10

Cost-minimization analysis of degludec/liraglutide versus g..:

Torre, Enrico ; Bruno, Giacomo Matteo ; Di Matteo, Sergio...
ClinicoEconomics and Outcomes Research. 10 (2018) - p. 413-421 , 2018

Link: https://doi.org/10.2147/..

11

Economic Evaluation for Palbociclib Plus Fulvestrant vs Rib..:

Colombo, Giorgio Lorenzo ; Valentino, Maria Chiara ; Fabi, Alessandra...
info:eu-repo/semantics/altIdentifier/doi/10.2147/TCRM.S391769. , 2023

Link: https://www.dovepress.co..

12

Economic Evaluation for Palbociclib Plus Fulvestrant vs Rib..:

Colombo, Giorgio Lorenzo ; Valentino, Maria Chiara ; Fabi, Alessandra...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10066701/. , 2023

Link: http://www.ncbi.nlm.nih...

13

Economic Burden of Non-Alcoholic Steatohepatitis (NASH) Amo..:

Torre, Enrico ; Di Matteo, Sergio ; Bruno, Giacomo Matteo...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9482784/. , 2022

Link: http://www.ncbi.nlm.nih...

14

Economic Burden of Non-Alcoholic Steatohepatitis (NASH) Amo..:

Torre, Enrico ; Di Matteo, Sergio ; Bruno, Giacomo Matteo...
info:eu-repo/semantics/altIdentifier/doi/10.2147/CEOR.S371778. , 2022

Link: https://www.dovepress.co..

15

Economic Impact of COVID-19 Lockdown on Italian NHS: Focus ..:

Torre, Enrico ; Colombo, Giorgio Lorenzo ; Di Matteo, Sergio...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213950/. , 2021

Link: http://www.ncbi.nlm.nih...